AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
AngioDynamics, Inc. (NASDAQ: ANGO) filed this Current Report on Form 8-K on January 6, 2026. The filing announces financial results for the fiscal second quarter ended November 30, 2025. The company is incorporated in Delaware and operates in the medical device sector.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) for detailed data. The text of this Form 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached exhibits for these figures.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to the prior comparable period. Such details are contained within the referenced press release and presentation materials.
Guidance, Outlook, and Risks
The document includes a comprehensive "Forward-Looking Statements" section. Management notes that actual results may differ materially from expectations due to various risks, including:
- Global pandemic impacts and supply chain challenges (inflation, tariffs, labor shortages).
- Regulatory actions by the FDA and other agencies.
- Competitive pressures and technological advances by rivals.
- Results of clinical trials and product development.
- Intellectual property disputes and litigation outcomes.
- Foreign currency fluctuations and economic conditions.
The company explicitly states it does not assume an obligation to update forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Slides) for updated full-year guidance and strategic outlook.
- Verify the impact of supply chain costs and inflation on gross margins as detailed in the exhibits.
- Check for any updates on pending litigation or regulatory approvals mentioned in the risk factors.